Intensified therapy for infants with acute lymphoblastic leukemia: Results from the Dana-Farber Cancer Institute Consortium

Cancer

Volumn 80, Issue 12, 1997, Pages 2285-2295

  Silverman, Lewis B ^a,b   McLean, Thomas W ^a   Gelber, Richard D ^b   Donnelly, Mia J ^b   Gary Gilliland, D ^c   Tarbell, Nancy J ^a   Sallan, Stephen E ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Infants; Late effects; MLL gene rearrangement; Survival; TEL AML1 gene fusion

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CATARACT; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; GENE FUSION; GENE REARRANGEMENT; GROWTH RETARDATION; HEART DISEASE; HUMAN; INFANT; LEARNING DISORDER; MALE; OBESITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RADIATION SICKNESS; SEPTICEMIA; SHORT STATURE; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTARABINE; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTO-ONCOGENES; REMISSION INDUCTION; SURVIVAL RATE; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0031454013     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971215)80:12<2285::AID-CNCR10>3.0.CO;2-Q     Document Type: Article

References (51)

1. Reaman G, Zeltzer P, Bleyer WA, Amendola B, Level C, Sather H, et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol 1985;3:1513-21.
2. Crist W, Pullen J, Boyett J, Falletta J, van Eys J, Borowitz M, et al. Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: a Pediatric Oncology Group study. Blood 1986;67:135-40.
3. Chessells JM, Eden OB, Bailey CC, Lilleyman JS, Richards SM. Acute lymphoblastic leukemia in infancy: experience in MRC UKALL trials: report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 1994;8:1275-9.
4. Ferster A, Bertrand Y, Benoit Y, Boilletot A, Behar C, Margueritte G, et al. Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol 1994;86:284-90.
5. Ludwig WD, Bartram CR, Harbott J, Koller U, Haas OA, Hansen-Hagge T, et al. Phenotypic and genotypic heterogeneity in infant acute leukemia I. Acute lymphoblastic leukemia. Leukemia 1989;3:431-9.
6. Pui C-H, Raimondi SC, Murphy SB, Ribiero RC, Kalwinsky DK, Dahl GV, et al. An analysis of leukemic cell chromosomal features in infants. Blood 1987;69:1289-93.
7. Hereema NA, Arthur DC, Sather H, Albo V, Feusner J, Lange BJ, et al. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Children's Cancer Group. Blood 1994;83:2274-84.
8. Arthur DC, Bloomfield CD, Lindquist LL, Nesbit ME. Translocation 4;11 in acute lymphoblastic leukemia: clinical characteristics and prognostic significance. Blood 1982;59:96-9.
9. Pui C-H, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR, et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood 1991;77:440-7.
10. Raimondi SC, Peiper SC, Kitchingman GR, Behm FG, Williams DL, Hancock ML, et al. Childhood acute lymphoblastic leukemia with chromosomal breakpoints at 11q23. Blood 1989;73:1627-34.
11. Chen CS, Sorensen PHB, Domer PH, Reaman GH, Korsmeyer SJ, Heerema NA, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993;81:2386-93.
12. Rubnitz JE, Link MP, Shuster JJ, Carroll AJ, Hakami N, Frankel LS, et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1994;84:570-3.
13. Pui C-H, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribiero RC, et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994;12:909-15.
14. Cimino G, Lo Coco F, Biondi A, Elia L, Luciano A, Croce CM, et al. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood 1993; 82:544-6.
15. Hilden JM, Frestedt JL, Moore RO, Heerema NA, Arthur DC, Reaman GH, et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4;11)(q21;q23). Blood 1995;86:3876-82.
16. Sallan SE, Camitta BM, Cassady JR, Nathan DG, Frei E. Intermittent combination chemotherapy with Adriamycin for childhood acute lymphoblastic leukemia: clinical results. Blood 1978;51:425-33.
17. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43:5601-7.
18. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady RJ, Tarbell NJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986;315:657-63.
19. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994;12:740-7.
20. Fletcher JA, Kimball VM, Lynch E, Donnelly M, Pavelka K, Gelber RD, et al. Prognostic implications of cytogenetic studies in an intensively treated group of children with acute lymphoblastic leukemia. Blood 1989;74:2130-5.
21. Harnden DG, Klinger HP, editors. An international system for cytogenetic nomenclature. Basel, Switzerland: Karger, 1985.
22. Sambrook J, Fritsch EF, Maniatis T, editors. Molecular cloning: a laboratory manual. 2nd edition. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1989.
23. Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayahi H, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993; 329:909-14.
24. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996;88:4252-8.
25. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
26. Greenwood M. The natural duration of cancer. In: Reports on Public Health and Medical Subjects, 33. London: Her Majesty's Stationary Office, 1926:1-26.
27. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
28. Cox DR. Regression models and life-tables [with discussion]. JR Stat Soc (B) 1972;34:187-220.
29. Pinkel D, Woo S. Prevention and treatment of meningeal leukemia in children. Blood 1994;84:355-66.
30. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui C-H, Abromowitch M, et al. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991;337:61-6.
31. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 988 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33.
32. Pieters R, Kaspers GJL, van Wering ER, Huismans DR, Loonen AH, Hahlen K, et al. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 1993;7:392-7.
33. Dreyer ZE, Steuber CP, Bowman WP, Murray JC, Coppes M, Dinndorf P, et al. Infant ALL-A pilot study, improved outcome with induction intensification [abstract]. Proc Am Soc Pediatr Hematol/Oncoi 1996;5:15.
34. Lange BJ, Raimondi SC, Heerema N, Nowell PC, Minowada J, Steinherz PE, et al. Pediatric leukemia/lymphoma with t(8;14)(q24;q11). Leukemia 1992;6:613-8.
35. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995;9:1985-9.
36. Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM, et al. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood 1997;89:1143-6.
37. Malonev KW, Rubnitz JE, Cleary ML, Frankel L, Hakami N, Link MP, et al. Lack of ETV6 (TEL) rearrangements in infant acute lymphoblastic leukemia (ALL) [abstract]. Blood 1996;88:72a.
38. Mulhern RK, Kovnar E, Langston J, Carter M, Fairclough D, Leigh L, et al. Long-term survivors of leukemia treated in infancy: factors associated with neurophsychologic status. J Clin Oncol 1992;10:1095-102.
39. Halberg FE, Kramer JH, Moore IM, Wara WM, Matthay KK, Ablin AR Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 1991;22:13-6.
40. Waber DP, Tarbell NJ, Fairclough D, Atmore K, Castro R, Isquith P, et al. Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice. J Clin Oncol 1995;13:2490-6.
41. Mulhern RK, Fairclough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy or no cranial irradiation. J Clin Oncol 1991;9:1348-56.
42. Tarbell NJ, Gelber RD, Barr R, Blattner S, Clavell L, LeClerc JM, et al. Efficacy of hyperfractionated cranial irradiation (XBT) in childhood acute lymphoblastic leukemia (ALL) [abstract]. Blood 1992;80:207a.
43. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-15.
44. Speyer IL, Green MD, Kramer E, Rey M, Sanger I, Ward C, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745-52.
45. Tucker MA, Meadows AT, Boice JD Jr., Stovall M, Oberlin O, Stone BJ, et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987;78:459-64.
46. Pui C-H, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989;321:136-42.
47. Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, Gjedde SB, Philip P, Hansen M, et al. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocation to band 11q23 after therapy with 4-epi-doxorubicin and cis-platinum or cyclophosphamide for breast cancer. J Clin Oncol 1992;10:1444-51.
48. Sandoval C, Pui CH, Bowman LC, Heaton D, Hurwitz CA, Raimondi SC, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalcating topoisomerase II inhibitors and irradiation. J Clin Oncol 1993;11:1039-45.
49. Kaldor JM, Day NE, Pettersson F, Clarke EA, Pedersen D, Mehnert W, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990;322:1-6.
50. Kreissman SG, Gelber RD, Cohen HJ, Clavell L, Leavitt P, Sallan SE. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer 1992;70:2208-13.
51. Emminger W, Emminger-Schmidmeier W, Haas OA, Urban C, Ambros P, Peters C, et al. Treatment of infant leukemia with busulfan, cyclophosphamide ± etoposide and bone marrow transplantation. Bone Marrow Transplant 1992; 9:313-8.